Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$356 Mln
P/E Ratio
--
P/B Ratio
8.56
Industry P/E
--
Debt to Equity
--
ROE
-12.2 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-221.70 Mln
EBITDA
$-305.13 Mln
Net Profit
$-318.32 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Checkpoint Therapeutics (CKPT)
| 28.13 | 1.49 | 41.87 | 186.71 | -31.04 | -25.53 | -- |
|
BSE Sensex*
| 2.74 | 3.85 | 4.73 | 7.66 | 12.11 | 19.70 | 11.44 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Checkpoint Therapeutics (CKPT)
| 39.36 | -55.19 | -83.57 | 17.36 | 54.07 | -5.49 | -52.90 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and... internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. Address: 95 Sawyer Road, Waltham, MA, United States, 02453 Read more
President, CEO & Director
Mr. James F. Oliviero III, C.F.A.
President, CEO & Director
Mr. James F. Oliviero III, C.F.A.
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Checkpoint Therapeutics Inc (CKPT) stood at $ 7 Mln as on 31-Dec-24
The share price of Checkpoint Therapeutics Inc (CKPT) is $4.10 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Checkpoint Therapeutics Inc (CKPT) has given a return of -31.04% in the last 3 years.
Checkpoint Therapeutics Inc (CKPT) has a market capitalisation of $ 356 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Checkpoint Therapeutics Inc (CKPT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Checkpoint Therapeutics Inc (CKPT) and enter the required number of quantities and click on buy to purchase the shares of Checkpoint Therapeutics Inc (CKPT).
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. Address: 95 Sawyer Road, Waltham, MA, United States, 02453
The CEO & director of Mr. James F. Oliviero III, C.F.A.. is Checkpoint Therapeutics Inc (CKPT), and CFO & Sr. VP is Mr. James F. Oliviero III, C.F.A..
There is no promoter pledging in Checkpoint Therapeutics Inc (CKPT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Checkpoint Therapeutics Inc. (CKPT) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Checkpoint Therapeutics Inc (CKPT) was $0 Mln.
$-0.01
(
